
Sanofi axes four major players from its executive committee
pharmafile | February 13, 2020 | News story | Manufacturing and Production, Medical Communications | Sanofi, appointments, pharma
Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief Executive Officer Paul Hudson, who joined the company in September last year.
The reshuffle was announced during Sanofi’s fourth-quarter earnings call. The intention is to streamline the committee’s operations and cut down on internal bureaucracy. As Hudson said, the move should help “allocate more of our central expertise into our business units and increase the accountability.”
Following the move, the committee will shrink to 10 members. Those to lose their positions include Ameet Nathwani, Chief Digital and Medical Officer, who joined Sanofi in 2016 before climbing to his current role in 2019, as well as Kathleen Tregoning, Executive Vice President, External Affairs, and Dieter Weinand, Executive Vice President of Primary Care Unit.
Also facing the axe is Dominique Carouge, Executive Vice President, Business Transformation, who has been with the company since 1991, having previous served as Deputy Chief Financial Officer.
Matt Fellows
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …






